sorafenib-resistant FLT3 mutants don't bind sorafenib

Stable Identifier
Reaction [transition]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The following FLT3 mutants are resistant to sorafenib:

FLT3 A848P (von Bubnof et al, 2010)
FLT3 F691I Albers et al, 2013)
FLT3 F691L (Albers et al, 2013; Baker et al, 2013)
FLT3 Y842H (partial: Albers et al, 2013)
FLT3 D835A (Nguyen et al, 2017)
FLT3 D835F (Smith et al, 2012; 2013; 2015)
FLT3 D835H (Baker et al, 2013; Smith et al, 2015)
FLT3 D835V (Smith et al, 2012; 2013; 2015)
FLT3 D835Y (Moore et al, 2012; Nguyen et al, 2017; Smith et al, 2012; 2013; 2015)
Literature References
PubMed ID Title Journal Year
20520641 Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib

Menzel, H, Sigl, M, Rummelt, C, Duyster, J, von Bubnoff, N, Peschel, C

Leukemia 2010
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Levis, M, Nguyen, B, Williams, AB, Small, D, Brown, P, Li, L, Young, DJ, Ma, H

Oncotarget 2017
22354205 Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

Pearson, AD, Avery, S, Workman, P, Faisal, A, Mair, D, Atrash, B, Blagg, J, Bavetsias, V, Linardopoulos, S, Mirabella, F, Valenti, M, Eccles, SA, Moore, AS, de Haven Brandon, A, Sun, C, Swansbury, J, Gonzalez de Castro, D, Raynaud, FI

Leukemia 2012
Normal reaction
Functional status

Loss of function of sorafenib-resistant FLT3 mutants [plasma membrane]

Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!